Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sintilimab, Lenvatinib and Radiotherapy for HCC with PVTT
NCT05225116Phase 1Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoints: Safety (CTCAE v5.0) up to 5 years and Number of patients who complete pre-op treatment and proceed to surgery up to 5 years. Started Jan 2023; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05225116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225116.